TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37455531

Group type: EXPERIMENTAL
Intervention: Patients with depressive symptoms (BDI ≥10) in CAD
Number of subjects: 587

Group type: COMPARATOR
Intervention: Patients without depressive symptoms in CAD
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Patients with depressive symptoms in DM
Number of subjects: 587

Group type: COMPARATOR
Intervention: Patients without depressive symptoms in DM
Number of subjects: 587
Study: 37455588

Group type: EXPERIMENTAL
Intervention: Ritlecitinib 30 mg and higher
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 37455644

Group type: COMPARATOR
Intervention: Group 40 (maintained at 40±5 mmHg CO2)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Group 50 (maintained at 50±5 mmHg CO2)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Group 60 (maintained at 60±5 mmHg CO2)
Number of subjects: 297
Study: 37456251

Group type: EXPERIMENTAL
Intervention: 3D conformational RT
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: V30 Gy >15%
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Pulmonary medical history
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: High V30 Gy
Number of subjects: 1565
Study: 37456281

Group type: EXPERIMENTAL
Intervention: MRgFUS thalamotomy
Number of subjects: 9
Study: 37456358

Group type: EXPERIMENTAL
Intervention: Carrying genetic variants of OPRM1 (rs1799971, A>G)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Carrying genetic variants of ABCB1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Carrying genetic variant rs2952768
Number of subjects: 102
Study: 37456507

Group type: EXPERIMENTAL
Intervention: Risedronate (bisphosphonate), administered monthly for six months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 37456641

Group type: EXPERIMENTAL
Intervention: Targeted multidomain (T-MD) intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (behavioral management)
Number of subjects: 250
Study: 37456676

Group type: EXPERIMENTAL
Intervention: Odevixibat 120 μg/kg per day
Number of subjects: 69
Study: 37456802

Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC) applied twice a day for 28 days
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dermocosmetic (DC)
Number of subjects: 107
Study: 37456813

Group type: EXPERIMENTAL
Intervention: PRIORITY intervention (hybrid centre and home-based personalized exercise and physical activity intervention)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Written exercise prescription (control group)
Number of subjects: 312
Study: 37456818

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program (nutrition guidance, diet journal, mindfulness training, exercise guidance)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care (patient education, counseling, personal guidance on exercise, breathing, and coughing)
Number of subjects: 152
Study: 37456919

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37457284

Group type: EXPERIMENTAL
Intervention: Lifestyle factors (diet, physical activity, tobacco, and alcohol)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Microbiome
Number of subjects: 1000
Study: 37457622

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg tablet) given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Placebo, given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Number of subjects: 3200
Study: 37457966

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine
Number of subjects: 115

Group type: COMPARATOR
Intervention: CHB adults (control group)
Number of subjects: 115
Study: 37458272

Group type: EXPERIMENTAL
Intervention: Solanezumab
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1169
Study: 37458369

Group type: EXPERIMENTAL
Intervention: Sublay biologic mesh
Number of subjects: 107

Group type: COMPARATOR
Intervention: No mesh
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Small bites (0.5 × 0.5cm)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Large bites (1 × 1 cm)
Number of subjects: 107
Study: 37458583

Group type: EXPERIMENTAL
Intervention: TDF+pegIFN+NAPs (early triple therapy group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TDF+pegIFN (delayed triple therapy group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monophasic HBsAg decline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nonmonophasic HBsAg kinetic pattern
Number of subjects: 40
Study: 37458698

Group type: EXPERIMENTAL
Intervention: Active TOMAC
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sham TOMAC
Number of subjects: 133
Study: 37458805

Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant human ASA
Number of subjects: 12
Study: 37459054

Group type: EXPERIMENTAL
Intervention: Trainee-performed intestinal ultrasound (IUS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Magnetic resonance enterocolonography (MREC)
Number of subjects: 129
Study: 37459059

Group type: EXPERIMENTAL
Intervention: Screen and treat for BV using self-collected vaginal swabs (n=3333)
Number of subjects: 6671

Group type: COMPARATOR
Intervention: Usual care (n=3338)
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Screen and treat for BV in nulliparous women (n=3438)
Number of subjects: 6671

Group type: COMPARATOR
Intervention: Usual care in multiparous women
Number of subjects: 6671

Group type: EXPERIMENTAL
Intervention: Screen and treat for BV
Number of subjects: 6671

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6671
Study: 37459086

Group type: EXPERIMENTAL
Intervention: Direct oral challenge with penicillin
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard-of-care: penicillin skin testing followed by oral challenge
Number of subjects: 377
Study: 37459089

Group type: EXPERIMENTAL
Intervention: Gun safety video
Number of subjects: 226

Group type: COMPARATOR
Intervention: Car safety video
Number of subjects: 226
Study: 37459141

Group type: EXPERIMENTAL
Intervention: Donanemab (n=860)
Number of subjects: 1736

Group type: COMPARATOR
Intervention: Placebo (n=876)
Number of subjects: 1736
Study: 37459153

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous magnesium sulfate (IVMg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose intravenous magnesium sulfate (IVMg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (IVMg and placebo)
Number of subjects: 90
Study: 37459203

Group type: EXPERIMENTAL
Intervention: sutimlimab
Number of subjects: 22
Study: 37459248

Group type: EXPERIMENTAL
Intervention: Obexelimab 5 mg/kg intravenously every 2 weeks until week 32 or loss of improvement (LOI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Obexelimab
Number of subjects: 104
Study: 37459306

Group type: EXPERIMENTAL
Intervention: Family Health Partners (FGP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no FGP intervention)
Number of subjects: 102
Study: 37459335

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 37459873

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus vemurafenib and cobimetinib
Number of subjects: 65
Study: 37460024

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 37460214

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Higher pre-stroke disability (mRS 3-5)
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Absence of bridging intravenous thrombolysis
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Longer time to treatment
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: High post-stroke disability at discharge (mRS 3-5)
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Futile recanalization (TICI score of 0-2a)
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Shorter hospital stay
Number of subjects: 13082

Group type: EXPERIMENTAL
Intervention: Discharge to institutional care or hospital
Number of subjects: 13082
Study: 37460257

Group type: EXPERIMENTAL
Intervention: Automated blood test measuring serum GFAP and UCH-L1 within 12 hours after mTBI
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Automated blood test measuring serum GFAP and UCH-L1
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Reference values for GFAP and UCH-L1
Number of subjects: 2370
Study: 37460263

Group type: EXPERIMENTAL
Intervention: Personalised prehabilitation programme
Number of subjects: 30
Study: 37460276

Group type: EXPERIMENTAL
Intervention: Nebulised nezulcitinib 3 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 37460353

Group type: EXPERIMENTAL
Intervention: PHH-1V vaccine candidate
Number of subjects: 0
Study: 37460370

Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at 100% coagulation mode, distance of 2-3 cm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at energy 80% during 2-4 s at distance of 2 cm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neutral argon plasma (NAP) at energy 100% during 2-4 s at distance of 3 cm
Number of subjects: 10
Study: 37460385

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 0
Study: 37460410

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 37460572

Group type: EXPERIMENTAL
Intervention: Gallium-68 labelled RGD PET/CT imaging
Number of subjects: 0
Study: 37460603

Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599) administered at doses of 1 and 5 mg/kg intraperitoneally for three months.
Number of subjects: 0
Study: 37460683

Group type: EXPERIMENTAL
Intervention: Short-term neoadjuvant endocrine therapy (NET) for 4 weeks (± 1 week)
Number of subjects: 37
Study: 37460782

Group type: EXPERIMENTAL
Intervention: Tanezumab (IV administration)
Number of subjects: 5229

Group type: EXPERIMENTAL
Intervention: Tanezumab (SC administration)
Number of subjects: 5229

Group type: EXPERIMENTAL
Intervention: Tanezumab (IV and SC)
Number of subjects: 5229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5229
Study: 37461024

Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction (LL-BFR) delivered twice daily at 20% 1-RM
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional heavier load resistance training (HL-RT) three-times per week at 70% 1-RM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction (LL-BFR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional heavier load resistance training (HL-RT)
Number of subjects: 150
Study: 37461034

Group type: EXPERIMENTAL
Intervention: XLJDOD compound granule
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 37461072

Group type: EXPERIMENTAL
Intervention: APP model of care (physiotherapist as first point of contact)
Number of subjects: 40
Study: 37461089

Group type: EXPERIMENTAL
Intervention: SHEPP intervention (health education on healthy lifestyle and physical activity sessions for children, training of teachers, and awareness sessions for parents over 10 months)
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: SHEPP intervention
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Routine activity (control)
Number of subjects: 1191
Study: 37461207

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4 counts
Number of subjects: 0
Study: 37461383

Group type: EXPERIMENTAL
Intervention: eMOMS (Electronic Monitoring of Mom's Schedule)
Number of subjects: 26
Study: 37461450

Group type: EXPERIMENTAL
Intervention: GUÍA genetic counseling
Number of subjects: 551

Group type: COMPARATOR
Intervention: Standard of care (SOC) genetic counseling
Number of subjects: 551
Study: 37461458

Group type: EXPERIMENTAL
Intervention: Comunică intervention (motivational interviewing and cognitive-behavioral therapy skills across eight live text-based counseling sessions)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Content-matched education attention control (eight time-matched educational modules)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Comunică intervention
Number of subjects: 305
Study: 37461538

Group type: EXPERIMENTAL
Intervention: Task shifting
Number of subjects: 7
Study: 37461594

Group type: EXPERIMENTAL
Intervention: Practice coaching intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 37461631

Group type: EXPERIMENTAL
Intervention: User-centred implementation strategy for tuberculosis contact investigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard TB contact investigation)
Number of subjects: 0
Study: 37461659

Group type: EXPERIMENTAL
Intervention: High bronchodilator response (BDR) group (N=277)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Low bronchodilator response (BDR) group (N=278)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: LOCCS cohort (adult asthma cohort)
Number of subjects: 1134
Study: 37461666

Group type: EXPERIMENTAL
Intervention: Neurologic Dance Training (NDT-Tango)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home Exercise (HEX)
Number of subjects: 0
Study: 37461672

Group type: EXPERIMENTAL
Intervention: Peer group intervention implemented by trained community volunteers
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 776
Study: 37461904

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention to support breastfeeding
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 37461954

Group type: EXPERIMENTAL
Intervention: ozanimod 0.92 mg
Number of subjects: 247

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 247
Study: 37461956

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg once daily
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Continuous ozanimod treatment
Number of subjects: 526

Group type: COMPARATOR
Intervention: Ozanimod induction followed by placebo maintenance
Number of subjects: 526

Group type: COMPARATOR
Intervention: Continuous placebo treatment
Number of subjects: 526
Study: 37461957

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.23 mg on Day 1
Number of subjects: 496
Study: 37461987

Group type: EXPERIMENTAL
Intervention: Whoop Strap 3.0 wearable technology for remote physiologic monitoring (RPM) used for 12 months.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Whoop Strap 3.0 wearable technology for RPM.
Number of subjects: 7
Study: 37462028

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 450
Study: 37462232

Group type: COMPARATOR
Intervention: Statins (simvastatin or atorvastatin) versus placebo
Number of subjects: 396

Group type: COMPARATOR
Intervention: Statins plus metformin versus metformin alone
Number of subjects: 396

Group type: COMPARATOR
Intervention: Statins plus oral contraceptive pill (OCP) versus OCP alone
Number of subjects: 396

Group type: COMPARATOR
Intervention: Statins versus metformin
Number of subjects: 396

Group type: COMPARATOR
Intervention: Statins versus oral contraceptive pill plus flutamide
Number of subjects: 396
Study: 37462260

Group type: EXPERIMENTAL
Intervention: eHealth Mindful Movement and Breathing (eMMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empathic Attention Control (AC)
Number of subjects: 0
Study: 37462350

Group type: EXPERIMENTAL
Intervention: Infants with pain symptoms (colic, abdominal pain)
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Infants with multimorbidity (common infections, eczema, food sensitivity)
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Mothers of infants with colic and those visiting healthcare for pain
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Infants with pain symptoms
Number of subjects: 1852

Group type: EXPERIMENTAL
Intervention: Mothers of infants with colic and visiting healthcare
Number of subjects: 1852
Study: 37462385

Group type: EXPERIMENTAL
Intervention: EMulate Therapeutics Voyager™ System
Number of subjects: 0
Study: 37462430

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.03 U/kg IV bolus followed by 0.3 mU/kg/min infusion)
Number of subjects: 28
Study: 37462471

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU) care
Number of subjects: 768

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 768
Study: 37462494

Group type: EXPERIMENTAL
Intervention: Gadopiclenol at 0.05 mmol/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gadobutrol at 0.1 mmol/kg
Number of subjects: 0
Study: 37462495

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (anesthetic infiltration)
Number of subjects: 0
Study: 37462600

Group type: EXPERIMENTAL
Intervention: Elemental formula for 6 consecutive weeks
Number of subjects: 15
Study: 37462612

Group type: EXPERIMENTAL
Intervention: Bioprosthetic surgical aortic valve intervention
Number of subjects: 421
Study: 37462798

Group type: EXPERIMENTAL
Intervention: MRI-based integrated model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Radiologist-interpreted differentiation model
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Integrated nomogram model
Number of subjects: 140
Study: 37462799

Group type: EXPERIMENTAL
Intervention: Home-based computerized EF intervention (5 days/week, 30 min/day, total dose 30 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study: 37463012

Group type: EXPERIMENTAL
Intervention: Structured foot examination form
Number of subjects: 8
Study: 37463054

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 448
Study: 37463058

Group type: EXPERIMENTAL
Intervention: DC/MM fusion vaccination with GM-CSF and lenalidomide maintenance
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control (GM-CSF and lenalidomide or lenalidomide maintenance alone)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: DC/MM fusion vaccination
Number of subjects: 203
Study: 37463240

Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced CMRA (3 mg/kg IV)
Number of subjects: 30
Study: 37463309

Group type: EXPERIMENTAL
Intervention: Early intervention telemedicine-based follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 0
Study: 37463344

Group type: EXPERIMENTAL
Intervention: Home-based light-intensity training with daily whey protein supplementation (LITW)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Center-based heavy resistance training with whey protein supplementation (HRTW)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Daily whey protein supplementation alone (WHEY)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Resistance training continuation (CONT)
Number of subjects: 104
Study: 37463362

Group type: EXPERIMENTAL
Intervention: Nasal inoculation with commensal bacteria
Number of subjects: 31
Study: 37463435

Group type: EXPERIMENTAL
Intervention: Novel motorized spiral enteroscopy (NMSE)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 72
Study: 37463599

Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope
Number of subjects: 551
Study: 37463650

Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo vaginal ovules for 5 days postoperatively with cefazolin 2 g intravenous single dose before surgery
Number of subjects: 574
Study: 37463687

Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 6 months after completion of rituximab
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 12 months after completion of rituximab
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 6 months after completion of rituximab (PP analysis)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prophylactic TDF for 12 months after completion of rituximab (PP analysis)
Number of subjects: 90
Study: 37463802

Group type: EXPERIMENTAL
Intervention: Midline catheter (MC)
Number of subjects: 2000
Study: 37463839

Group type: EXPERIMENTAL
Intervention: CogRx
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 39
Study: 37464064

Group type: EXPERIMENTAL
Intervention: Colovac+
Number of subjects: 25
Study: 37464107

Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous Drainage
Number of subjects: 0
Study: 37464143

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 225
Study: 37464228

Group type: EXPERIMENTAL
Intervention: Serious game based on Gabor patches (study group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo software (placebo group)
Number of subjects: 60
Study: 37464283

Group type: EXPERIMENTAL
Intervention: High voltage pulsed radiofrequency (PRF)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nerve block with steroid and local anesthetic drugs
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 37464349

Group type: EXPERIMENTAL
Intervention: Fully immersive VR exergames (go/no-go punch game, go/no-go stepping game, number punch game), 10 sessions, 2-3 times a week, 30 min per session.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VR exergames
Number of subjects: 12
Study: 37464355

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) implantation into nitrate-induced maximally dilated vessels
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional DES implantation
Number of subjects: 400
Study: 37464378

Group type: EXPERIMENTAL
Intervention: Sintilimab plus CapeOx and bevacizumab
Number of subjects: 494

Group type: COMPARATOR
Intervention: CapeOx and bevacizumab
Number of subjects: 494